Pierre Sakali, MD
Allergy & Immunology · Tucson, AZNPI 1689769663
Payments from drug & device makers
Across 497 payments — averaging $50.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$15K
- AstraZeneca$2K
- Sanofi$1K
- CSL Behring$1K
- Takeda Pharmaceuticals U.S.A., Inc.$940
- Regeneron Healthcare Solutions, Inc.$687
- plus $4K from 29 others
What the payments were for
- Consulting fees$220%
- Speaking & faculty fees$13,37554%
- Food & beverage$11,41046%
- Education$1291%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 88 | $14,734 |
| AstraZeneca | 59 | $2,361 |
| Sanofi | 36 | $1,079 |
| CSL Behring | 43 | $1,023 |
| Takeda Pharmaceuticals U.S.A., Inc. | 50 | $940 |
| Regeneron Healthcare Solutions, Inc. | 35 | $687 |
| Pharming Healthcare, Inc. | 21 | $683 |
| Amgen | 28 | $635 |
| Biocryst US Sales Co., LLC | 19 | $410 |
| Novartis | 19 | $307 |
| Optinose US, Inc. | 12 | $276 |
| Grifols USA, LLC | 11 | $255 |
| Genentech USA, Inc. | 11 | $208 |
| Kaleo, Inc. | 8 | $179 |
| Teva Pharmaceuticals USA, Inc. | 11 | $171 |
| Shire North American Group Inc | 7 | $129 |
| Galderma Laboratories, L.p. | 1 | $95 |
| Pfizer | 5 | $88 |
| LEO Pharma Inc. | 4 | $84 |
| Lilly USA, LLC | 3 | $70 |
| Covis Pharma GmbH | 2 | $69 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Bio Products Laboratory USA, Inc. | 6 | $58 |
| Boehringer Ingelheim | 3 | $54 |
| Abbott | 1 | $48 |
| Cycle Pharmaceuticals Inc | 2 | $44 |
| ADMA Biomanufacturing LLC | 2 | $36 |
| Biocryst Pharmaceuticals, Inc. | 2 | $34 |
| Blueprint Medicines Corporation | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Kedrion Biopharma, Inc. | 1 | $18 |
| Ionis Pharmaceuticals, Inc. | 1 | $18 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $15 |
| Viatris Specialty LLC | 1 | $14 |
| GC Biopharma USA, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,936 in reported general payments places this provider in the 80th percentile of 90 allergy & immunology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 94 | $346,501 |
| Dupixent PenDupilumab | 42 | $194,711 |
| Dupixent SyringeDupilumab | 33 | $163,434 |
| FasenraBenralizumab | 20 | $130,662 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 148 | $123,171 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $111,710 |
| TezspireTezepelumab-Ekko | 22 | $91,017 |
| HyqviaIgg/Hyaluronidase,recombinant | 20 | $82,330 |
| Breo ElliptaFluticasone/Vilanterol | 161 | $70,372 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 22 | $64,022 |
| Arnuity ElliptaFluticasone Furoate | 156 | $44,484 |
| Spiriva RespimatTiotropium Bromide | 48 | $27,277 |
| Advair HfaFluticasone Propion/Salmeterol | 48 | $21,485 |
| Qvar RedihalerBeclomethasone Dipropionate | 52 | $19,627 |
| Epinephrine | 127 | $18,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFasenra, Tezspire, Symbicort, Pulmicort Flexhaler | $2,361 | $242,711117 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $14,734 | $238,027465 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia, Gammagard Liquid | $940 | $146,35242 claims |
| CSL BehringHizentra | $1,023 | $111,71013 claims |
| Boehringer IngelheimSpiriva Respimat | $54 | $27,27748 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $171 | $19,62752 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 90 allergy & immunology providers in Arizona.
Other allergy & immunology in Tucson
- Tara CarrTucson$308K
- Heather CassellTucson$261K
- George MakolTucson$13K
- Nicole LahoodTucson$13K
- Nabeeh LahoodTucson$13K
- Martin BartelsTucson$7K
- Puneet ShroffTucson$4K
- Kudagal MurthyTucson$3K
- Anjali JainTucson$2K
- Kaitlyn LeaheyTucson$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.